Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BD Biosciences Rolls Out New BD LSRFortessa Cell Analyzer
The new system occupies a 30”x 36″ benchtop footprint, allowing researchers to maximize utilization of the lab space, without sacrificing system power. The system includes a number of
The new system occupies a 30”x 36″ benchtop footprint, allowing researchers to maximize utilization of the lab space, without sacrificing system power. The system includes a number of
Earlier, in March 2009, Aveo had entered into an exclusive option and license agreement with Biogen Idec International, a subsidiary of Biogen Idec, regarding the development and commercialisation
UCB claimed that the study of Rotigotine in patients with moderate to severe RLS was the longest ever open label prospective follow-up of a placebo-controlled phase II trial
Biologics Process Developments has specialized in contract laboratory services in molecular biology, recombinant protein expression and purification, cell culture, bacterial fermentation, frozen cell/material storage, and consulting in biologics
LOR-253 is a small molecule compound that has shown selective and potent antitumor activity in a variety of human cancers, including colon cancer and non-small cell lung cancer,
MemorA-Z is a memory enhancement supplement developed by John Blass, professor Emeritus at Weill Medical College of Cornell University. CNS Pharmaceuticals said that the Brain Fizz stick pack
The study, funded by NIAID, is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract
Prograf is prescribed to prevent organ rejection in patients receiving allogenic liver, kidney, or heart transplants and was first approved and launched in Japan in 1993. Prograf is
Sorin Group said that the Angel product line consists of a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor
For patients previously receiving other treatments, the annual relapse rates were reduced by 44%. In addition, at two years Gilenia delayed the progression of disability by 30% for